Worldwide Fibrous Dysplasia Market 2018 – Top Players are Novartis AG, Pfizer Inc, Amgen Inc, AVEO Pharmaceuticals Inc, Bayer AG and more.

Global Fibrous Dysplasia Market is expected to grow at a CAGR of ~6.2 % during the forecast period 2017-2023. Fibrous dysplasia is a rare and chronic bone disorder in which fibrous tissue develops in place of normal bone, weakens the affected bone, and deform or fracture it. As per reports from The Johns Hopkins University, the exact cause of fibrous dysplasia is unknown, but it is believed to be due to a chemical irregularity in a specific bone protein. This bone protein abnormality may arise due to a gene mutation present at birth, although it is not known to be an inherited disorder.

It often results in uneven growth of bones, pain, brittle bones, and bone deformity. In fibrous dysplasia, the most commonly affected bones includes femur (thighbone), tibia (shin bone), ribs, skull, facial bones, humerus (the bone of the upper arm), pelvis, vertebrae in the spine (less often).

Key Players:

Some of key the players in the market are Novartis AG, Pfizer Inc, Amgen Inc, AVEO Pharmaceuticals Inc, Bayer AG, Bellicum Pharmaceuticals Inc, MediaPharma srl, Merck & Co., Inc, Merrimack Pharmaceuticals Inc, Oncolys BioPharma Inc, United Therapeutics Corp and others.

Get Discount on Fibrous Dysplasia Market Report @ https://www.marketresearchfuture.com/check-discount/4780 .

Segmentation:

The global fibrous dysplasia market is segmented on the basis by diagnosis, by treatment, and by end user. On the basis of diagnosis, it is segmented into X-rays, CT scans, MRI, bone scan, biopsy, and others. On the basis of treatment, it is segmented into medications, surgical, and others. The medications is further segmented into bisphosphonates, intravenous (IV) pamidronate, calcitonin, raloxifene, and others. On the basis of end user, it is segmented into hospitals & clinics, research centers, and others.

Regional Analysis:

The Americas dominate the global fibrous dysplasia market owing to the presence of huge patient population with bone disorders, high healthcare spending, and increasing government support for research & development.  

Europe holds the second largest share of the global fibrous dysplasia market as result of increasing focus of various government agencies on the treatment of rare diseases such as fibrous dysplasia. Moreover, the growing public awareness about fibrous dysplasia likely to boost the Europe market. 

Access Sample Copy @ https://www.marketresearchfuture.com/sample_request/4780 .

Market Highlights:

In some cases, fibrous dysplasia have only one bone involved (monostotic), whereas other cases have more than one bone involved (polyostotic). Fibrous dysplasia can affect any bone in the body and most common includes the bones in the skull and face, femur (thighbone), tibia (shinbone), humerus (upper arm), pelvis, and ribs.

Increasing prevalence of rare diseases, rising demand for better treatment, increasing investment in the biotechnology and pharmaceutical industries for R&D, and availability of funds drive the growth of the market. Moreover, increasing government support for research & development, changing lifestyle, and rapidly developing technology is expected to fuel the market growth during the forecast period. However, high cost of the treatment may slow the market growth during the period 2017-2023.

Browse Complete Premium 120 Pages Half-Cooked Research Report Enabled with Respective Tables and Figures is Available @ https://www.marketresearchfuture.com/reports/fibrous-dysplasia-market-4780

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.